A case of metachronous peripheral T-Cell non-Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin

Federico Meconi; Ida Provenzano; Daniela Nasso; Benedetta Mariotti; Livio Pupo; Roberto Secchi; Raffaella Cerretti; Anemona Lucia; William Arcese; Maria Cantonetti

doi:10.1002/ccr3.2898

A case of metachronous peripheral T-Cell non-Hodgkin lymphoma following chemotherapy for Hodgkin disease successfully treated with brentuximab vedotin

Clin Case Rep. 2020 May 5;8(8):1353-1356. doi: 10.1002/ccr3.2898. eCollection 2020 Aug.

Affiliations

¹ Department of Biomedicine and Prevention University Tor Vergata Rome Italy.
² Anatomic Pathology Department of Biomedicine and Prevention University of Rome Tor Vergata Rome Italy.

Abstract

Occasionally, non-Hodgkin lymphomas (NHL) occur simultaneously or subsequently to Hodgkin disease. We report on a case of a woman with Hodgkin lymphoma treated with ABVD, who developed 4 years later T-cell NHL with both nodal and extranodal involvement. Brentuximab vedotin could be an effective choice in treating metachronous T-cell NHL.

Keywords: Hodgkin lymphoma; brentuximab vedotin; non‐Hodgkin T‐cell lymphoma.

Publication types

Case Reports